EsoCap’s vision is to improve the lives of patients with serious illnesses through the development of a unique topical drug delivery platform for diseases of the upper gastrointestinal tract.

The Scientific Platform

EsoCap AG is a Swiss privately funded company based in Basel.

EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for the local treatment of diseases of the upper gastrointestinal tract.

Topical treatment in the upper gastrointestinal tract is extremely difficult to achieve due to ultra-short esophageal transit times with less than two seconds from the mouth to the stomach.

The EsoCap drug delivery platform will represent a CHANGE IN PARADIGM, similar as it happened with aerosol therapy in asthma.

Addressing Major Medical Needs

Application

At the moment there are major limitations in the local treatment of diseases of the upper gastrointestinal tract. Our unique and smart application technology in the upper gastrointestinal tract is broadly applicable with established and novel drug substances. It will be beneficial in at least 6 indications affecting 370 Mio patients.

Collaboration

EsoCap is developing this novel platform together with major partners:

the University of Greifswald in Germany with its institute, the C_DAT (Center of Drug Absorption and Transport), which is a leading European center of excellence operating since 2011.

Our Approach

Clinical Feasibility

Our approach is to show the clinical feasibility for our unique drug delivery technology in one indication and to seek for a major partner within the biopharmaceutical industry.

First Indication

The first indication will be eosinophilic esophagitis(EoE), a rare inflammatory disease of the esophagus. Current therapeutic options are limited to extremely strict dietary measures, off-label steroid treatment and one product registered only in the EU. These treatment options remain suboptimal for a vast majority of affected patients.

 EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for the local treatment of diseases of the upper gastrointestinal tract.

Team

EsoCap AG is led by one of the most experienced teams in the industry.

Our team has founded, led and grown some of the most important companies impacting patients’ lives through the development and the commercialization of major life-transforming medicines.

Management

Board Members

News

EsoCap AG organized a multidisciplinary scientific advisory board meeting in Zurich with thirteen international experts on June 27, 2019. As an introduction, Prof. Werner Weitschies, Center for Drug Absorption and Transport at the University of Greifswald, gave a presentation on the Esophageal Wafer Study conducted in healthy volunteers by the University of Greifswald. The excellent […]

Read more

EsoCap AG announced that a capital increase has been authorized by the Extraordinary General Assembly, held on April 11, 2019, followed by successful completion of a private placement financing. The proceeds of the private placement will be used to complete a clinical proof-of-concept trial in eosinophilic esophagitis (EoE). “We are delighted to have secured the […]

Read more

Basel, Switzerland, February 6, 2019 EsoCap AG and LTS Lohmann Therapy-Systeme AG announced the start of cooperation on industrial development of a unique drug delivery technology for diseases of the upper gastrointestinal tract. This collaboration leverages the collective expertise of a strong partner in the thin film industry with a highly innovative application technology. “We […]

Read more

Basel, Switzerland, July 13th, 2018 EsoCap AG announced that it has successfully completed a private placement financing round on July 13th, 2018. The proceeds of the capital increase will be used toward the completion of the technical development of EsoCap’s unique drug delivery technology and the initiation of a clinical proof-of-concept trial in eosinophilic esophagitis […]

Read more

EsoCap AG organized a scientific advisory board meeting with eight international experts in Eosinophilic Esophagitis (EoE) in Zürich on June 14th, 2018.

Prof. Dr. Werner Weitschies, Head of the Center of Drug Absorption and Transport at the University of Greifswald gave a keynote presentation on EsoCap’s unique drug delivery platform.

Read more

EsoCap announced that Sven Hoffmann and Isabelle Racamier have been appointed to the Company’s Board of Directors. “I am delighted to welcome Isabelle and Sven to the EsoCap Board. Both of them are highly talented executives bringing deep industry experience and a proven track record of building value” said Dr. Werner Tschollar, Chairman of the […]

Read more

EsoCap AG and the University of Greifswald in Germany announced that they have entered into a licensing agreement granting EsoCap the exclusive worldwide rights for the unique drug delivery technology developed by the University of Greifswald. Prof. Werner Weitschies, Head of the Center of Drug Absorption and Transport and his team at the University of […]

Read more

Contact

EsoCap AG is located in Basel, a major center for innovation.

 2017 © EsoCap AG | Malzgasse 9
CH-4052 Basel

Disclaimer

Read

Welcome to EsoCap AG. By using our website, you are accepting the following:

Copyright and Limitation of Liability

This website and its content are copyrighted by EsoCap AG. You may use, e.g. download or copy any content from this website for personal use only. Any other use of the content of this website is not permitted.

This website is for information purposes only and does not contain medical advice. While we are diligently updating our website, we are not bound by the information published and do not guarantee the content to be accurate or up-to-date. EsoCap AG cannot be held liable for any damage that could arise out of or in connection with the use of this website. EsoCap AG is particularly not responsible for damage resulting from incorrect, incomplete or outdated information or the loss of data. In case we are linking to other websites, EsoCap AG is not responsible for such third-party websites. All such limitations are subject to the extent permissible under the applicable law.

Privacy and Personal Data

EsoCap AG respects your privacy. You can browse this website without providing us with personal data. We may collect, store and process your personal data if you contact us by email. We may use your personal data for administrative purposes and to inform you about our services and products. We will not provide third parties with your personal data for purposes other than those listed.

We use cookies on this website. Cookies are small text files which are downloaded onto your hard disk when you access this website. Cookies allow recognizing your preferences or past actions and assist you with navigation on the website. You may disable the cookies function in your web browser, if you do not want to allow cookies being stored on your computer. With cookies deactivated, not all features of this website may function properly.

Contact Us

Drop us a line and we'll get back to you.